Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis

Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis

Source: 
Pharmaceutical Business Review
snippet: 

Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Jyseleca (filgotinib 200mg tablets) to treat ulcerative colitis (UC) in Great Britain.